ArticleInvestigational new drugs2018

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.

Anastasios Stathis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.